Oncopeptides AB (STU:OND) LT-Debt-to-Total-Asset : 0.50 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Oncopeptides AB's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.50.

Oncopeptides AB's long-term debt to total assets ratio declined from Dec. 2023 (0.53) to Dec. 2024 (0.50). It may suggest that Oncopeptides AB is progressively becoming less dependent on debt to grow their business.

Oncopeptides AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Oncopeptides AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB LT-Debt-to-Total-Asset Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.53

0.50

Oncopeptides AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.53	0.57	0.25	0.37	0.50

Oncopeptides AB LT-Debt-to-Total-Asset Calculation

Oncopeptides AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	10.597	/	21.229
	=	0.50

Oncopeptides AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	10.597	/	21.229
	=	0.50

Oncopeptides AB (STU:OND) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Oncopeptides AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (STU:OND) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden 0RN4:UK OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.